Inhibition of castration resistant prostate cancer by sintokamide A : an antagonist of the amino-terminus of the androgen receptor
The majority of lethal castration resistant prostate cancer(CRPC)is considered to involve a transcriptionally active androgen receptor (AR). All current therapies target AR ligand-binding domain (LBD) to inhibit receptor activity. Unfortunately these therapies fail perhaps b mechanisms involving exp...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2012
|
| Online Access: | http://hdl.handle.net/2429/42551 |